The Vandenberghe Lab is the Grousbeck Gene Therapy core laboratory focused on developing and translating genetic therapies to the clinic with an emphasis on blindness and other neurosensory disorders. Researchers in the Vandenberghe lab work at the intersection of medicine, virology, engineering, immunology, synthetic and systems biology to innovate genetic medicine.
The Gene Transfer Vector Core (GTVC) is to provide high quality research-grade viral vector preparations to support basic research and preclinical gene therapy studies for academia and industry. GTVC has its primary expertise in adeno-associated viral vector (AAV) preparation, qualification, and application.
June 5, 2020
AAV COVID-19 vaccine aims for the sweet spot between antibody and T cell immunity
January 2, 2019
Nerea Zabaleta Lasarte, PhD joins the lab from the University of Navarra where she worked on liver-directed gene and genome editing therapies in the lab of Gloria González-Aseguinolaza.
September 2, 2018
Amanda Dudek graduates from the Harvard Virology Graduate Program on her work on AAV entry factors. Congratulations Amanda!
Director (on leave)
Luk H. Vandenberghe, PhD
Luk H. Vandenberghe, PhD, is an Associate Professor at Harvard Medical School and Associate Member of the Broad Institute of Harvard and MIT in Boston, MA, USA. He directs the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear Infirmary in Boston, USA, a part of the the Ocular Genomics Institute, a bench to bedside research program to study, diagnose, and develop treatments for diseases of the eye.
He received a degree in cellular and genetic engineering from the University of Leuven, Belgium. His previous work led to the discovery of novel AAV serotypes such as AAV9, novel insights into AAV structure-function, and vector immunobiology. His laboratory aims to gain a deeper understanding of mechanisms of gene transfer, to develop technologies to overcome hurdles to gene therapy clinical applications, and to translate specific gene therapy programs in vision, hearing, and other fields. Recent studies leverage structural and evolutionary information on AAV as a starting point for the rational design of synthetic viral vector systems, a first generation of which is referred to as AncAAVs which are now progressing to the clinic for a number of indications. Dr. Vandenberghe previously co-founded GenSight Biologics and Akouos. He also is a founder, board member, and advisor to Odylia Therapeutics, a non-profit catalyzing translation for gene therapies within the challenging field of ultra-rare disorders. Dr. Vandenberghe has over 50 peer reviewed publication and more than a dozen licensed patents, mostly related to gene therapy methods, technologies, and applications.